Seattle, WA, United States of America

Navin Robert Charles Pinto

USPTO Granted Patents = 1 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Navin Robert Charles Pinto: Innovator in CAR T Cell Therapy

Introduction

Navin Robert Charles Pinto is a notable inventor based in Seattle, Washington. He has made significant contributions to the field of cancer treatment through his innovative work in CAR T cell therapy. His research focuses on improving methods for treating patients with cancer, showcasing his dedication to advancing medical science.

Latest Patents

Navin Pinto holds a patent for a "Sequencing method for CAR T cell therapy." This patent describes methods of treating cancer patients by administering a composition that includes CAR T cells, along with a small molecule linked to a targeting moiety by a linker. The patent also covers compositions that can be utilized in these treatment methods, highlighting the potential impact of his work on cancer therapies.

Career Highlights

Throughout his career, Navin Pinto has worked with reputable organizations, including the Purdue Research Foundation and Endocyte, Inc. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research in cancer treatment.

Collaborations

Navin Pinto has collaborated with notable professionals such as Richard Messmann and Christopher Paul Leamon. These partnerships have enriched his research and expanded the scope of his contributions to the medical community.

Conclusion

Navin Robert Charles Pinto is a distinguished inventor whose work in CAR T cell therapy represents a significant advancement in cancer treatment. His innovative methods and collaborations with other experts underscore his commitment to improving patient outcomes in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…